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Abstract
Objectives: to report the immunoexpression of metallothionein in oral leukoplakia and to correlate with histologi-
cal grade and clinical localization. Leukoplakia is the most common potentially malignant lesion of the oral cavity. 
As the histological study of oral leukoplakia can not predict precisely the malignant transformation of this lesion, 
and metallothionein is a protein that has been associated with carcinogenesis, this study could be auxiliary in this 
histological assessment of this lesion.
Study design: samples of oral leukoplakia (35 cases) and of normal oral mucosa (10 cases) were evaluated. Oral 
leukoplakia was graded in: hyperkeratosis without dysplasic change (9 cases), mild dysplasia (8 cases), moderated 
dysplasia (10 cases), and severe dysplasia (8 cases). Immunohistochemistry for the metallothionein was performed 
and the Mann-Whitney test was used in statistical analysis.
Results: metallothionein was identified in squamous cells of the all samples. The metallothionein stain in all cases 
exhibit a mosaic pattern and was predominantly in compartments cytoplasmatic and nuclear simultaneously. The 
total stain was significantly higher in moderate dysplasia when compared with normal oral mucosa, hyperkeratosis, 
and mild dysplasia.
Conclusion: it was suggested that the metallothionein may be a marker to moderate dysplasia and may play a role 
in oral carcinogenesis.
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Introduction
The oral leukoplakia (OL) is defined by the World Health 
Organization (WHO) as “a predominantly white lesion of 
the oral mucosa that cannot be characterized as any other 
definable lesion” (1). This disease is widely studied due to 
the risk of malignant transformation (2-8). The annual 
transformation rate of OL is proximal to 1% (3).
Clinical and demographic aspects of OL may be correlated 
with increased risk of malignant change. For example, OL 
located on the floor of the mouth, tongue, and  palate 
have a higher risk of malignant transformation than OL 
in other regions, and females with OL have a higher risk of 
developing oral squamous cell carcinoma (9,10). Histolo-
gically, OL may appear as hyperkeratosis, mild dysplasia, 
moderate dysplasia, and severe dysplasia (11). The ranges 
of these microscopic features have also been explored as 
a predictor of malignant transformation (2,8). However, 
the clinical aspects and histological study of OL can not 
predict precisely of malignant transformation (12). Stu-
dies regarding to markers of potential malignancy, such 
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as the proliferating cell nuclear antigen (PCNA), Ki-67, 
argyrophilic nucleolar organizer region (AgNOR) and 
p53, have been developed as auxiliary in this histological 
assessment (6,7,10,13-15).
Metallothionein (MT) belongs to group of low molecular 
weight proteins (6-7 kDa) characterized by high levels of 
cystein, which are bound to metal ions (16,17). This pro-
tein is constitutively found in the cytoplasm of mammalian 
cells (18). In normal oral mucosa, the MT immunoexpres-
sion in squamous epithelium cells was identified within 
basal and parabasal layers (19).The role of MT in the 
control of metals homeostasis has stimulated studies which 
suggest the correlation of MT with protection against 
oxidative damage caused by free radicals, inhibition of 
cell apoptosis, and carcinogenesis (18-20).
Up to now, an investigation of MT immunoexpression in 
OL has not been carried out. The aim of this study was 1) 
to report the MT immunoexpression in OL, 2) to compare 
the MT expression among the histological grades, and 3) 
to correlate the MT expression with clinical localization.
Material and Methods
Institutional ethical board 
The protocol of the study was approved by the Committee 
of Bioethics in Research at Universidade Federal de Minas 
Gerais (UFMG/COEP - number 207/04).
Specimens and histological evaluation
Samples with diagnosis of the OL (35 cases) and normal 
oral mucosa (10 cases; Figure 1A) were obtained from 
the files of the Oral Pathology Service of Universidade 
Federal de Minas Gerais (UFMG, Belo Horizonte, Bra-
zil) and from the Oral Pathology Service of  Pontifícia 
Universidade Católica of Minas Gerais (PUC-MG, Belo 
Horizonte, Brazil). The criteria of the WHO (2005) for 
the histological grading of leukoplakia were used (12,21). 
The histological degree of epithelial dysplasia was based 
on the proportion of the height of  the epithelial layer 
that presents the dysplasic changes. Mild dysplasia was 
characterized by few cytological alterations limited to 
the lower one-third of epithelium. When the lower two-
thirds of the epithelium showed cytological alterations 
the lesion was classified as moderate dysplasia. When de 
entire height of the epithelium presented dysplasic changes 
OL was graduated in severe dysplasia. The architectural 
changes observed in the classification were: loss of po-
larity of cells, increase of cellular density, dyskeratosis, 
basal cell hyperplasia, disordered maturation from basal 
to squamous cells, bulbous drop-shaped rete pegs, and 
secondary extensions on rete tips. The cellular changes 
considered were increase of  nucleus-cytoplasm ratio, 
cellular pleomorphism, cellular and nuclear enlargement, 
nuclear hyperchromatism and pleomorphism, enlarged 
and numerous nucleoli, increased mitotic figures, atypical 
mitotic figures and increased number and size of nucleoli. 
OL was submitted to histological evaluation on slides 
stained by haematoxilin-eosin (HE). The 35 cases of OL 
were graded in: hyperkeratosis without dysplasic change 
(9 cases), mild dysplasia (8 cases), moderate dysplasia (10 
cases; Figure 1B), and severe dysplasia (8 cases).
Clinical data were obtained from biopsy records. OLs 
located on the floor of the mouth, tongue, and palate 
were considered of high-risk region of malignant trans-
formation. Other sites were classified as low-risk region. 
The sample was composed of 26 male and 9 female; 26 
cases were located in the low-risk region and 9 cases in 
the high-risk region (9). Immunohistochemical evaluation 
was performed in all 45 cases.
Immunohistochemistry
Immunohistochemical reaction was performed using 
streptavidin-biotin standard protocol. Sections of 4µm 
from routinely processed paraffin embedded blocks were 
deparaffinized and dehydrated. Specimens were immer-
sed in a 1 mM ethylenediamine tetraacetic acid (EDTA, 
pH= 8.0) buffer (Vetec Química Fina, Rio de Janeiro, 
114) and submitted for 30 minutes at 98ºC. The avidin/
biotin was blocked in accordance with Miller et al. (22). 
Endogenous peroxidase activity was blocked using 0.3% 
hydrogen peroxide. Sections were incubated with primary 
antibody for MT at a 1:100 dilution (Dako, Carpinteria, 
CA, M0639) for 18 hours at 4ºC. A bound primary anti-
body was detected using LSAB®+system, HRP Peroxidase 
Kit (Dako Corporation, Carpinteria, CA, K0690) and 
3.3’-diaminobenzidine tetrahydrochloride chromogen 
(DAB, Sigma Chemical, St. Louis, USA, D5637). Positive 
controls were also used.
Immunohistochemical assessment
The immunohistochemical stain was analyzed by a 
blind and calibrated examiner (ACBRJ). The number of 
positive cells was counted in all cases. Indexes for MT 
expression were constructed based on the percentage of 
labeled cells among four to six counter fields for each 
slide. The analysis was carried out taking in count the cell 
compartment (cytoplasmatic and nuclear, cytoplasmatic 
only, or nuclear only) and the cellular layer involved (basal 
and suprabasal).
Statistic analysis
Statistic analysis was performed with a non-parametric 
method, Mann-Whitney test. BioEstat® software was 
used and p<0.05 was considered the limit for statistical 
significance (23).
Results
MT immunoexpression was presented in squamous cells 
of the all samples. The MT stain in all cases appeared as 
a mosaic pattern and predominantly in compartments 
cytoplasmatic and nuclear simultaneously. Immunostain 
exclusively restrict to the nucleus was not observed.
The MT total labeling was significantly higher in moderate 
dysplasia (66.7%, Figure 1C) when compared with normal 
oral mucosa (55.8%; p< 0.05; Figure 1D), hyperkeratosis 
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(56.7%; p< 0.05), and mild dysplasia (53.8%; p< 0.05). 
This MT overexpression was due to the high cytoplas-
matic and nuclear stain in the basal layer. No significant 
difference in total MT expression was observed between 
moderate dysplasia (66.7%) and severe dysplasia (59.7%; 
p> 0.05). Other comparisons among the groups and bet-
ween layers were performed, but there were not significant 
differences. No significant difference in MT total labeling 
was identified between regions of high (61.8%) and low 
risk (58.0%; p> 0.05).
Discussion
This study shows the immunoexpression of MT in OL. 
Although MT has been associated with carcinogenesis 
(20,24), there are no registers of this expression in poten-
tially malignant oral lesions. MT is mainly a cytoplasmatic 
protein found in mammalian cells (18). It was observed 
that the expression of MT was not restricted to the cyto-
plasm yet was observed in both cytoplasmatic and nuclear 
compartment of squamous cells in the basal and parabasal 
layers (19). Ioachim et al. (25), in a study of the benign, 
premalignant, and malignant epithelium of the larynx, 
also observed this double profile of  the immunostain. 
However, immunolocalization restricted to the nucleus 
was described in oral squamous cell carcinoma (20). 
Although MT has been characterized as a cytoplasmatic 
protein, it may cross the nuclear membrane by passive 
diffusion. The MT dislocation to nuclei was identified in 
human malignant lesions, such as lung carcinoma (26), 
and oral squamous cell carcinoma (26).The significance of 
nuclei localization is a more effective biological protection 
against oxidative stress and genomic damage. In addition 
to its interference in genomic regulation and other proteins 
linked to DNA (27,28). 
The overexpression of MT in moderate dysplasia may 
mean that the altered cells are more protected with more 
chances of survival, but it can also indicate alterations in 
genomic regulation and in other proteins linked to DNA, 
thus presenting its possible role in carcinogenesis. Further-
more, this overexpression may be correlated with initia-
tion or promotion of carcinogenesis. Ioachim et al. (25) 
evaluated the expression of MT in potentially malignant 
lesions of the larynx, but, in contrast with our results, did 
not find significant differences among the differing grades 
of dysplasia. The absence of difference in the MT total 
labeling between moderate dysplasia and severe dysplasia 
Fig. 1. (A) Normal oral mucosa without dysplasic changes (Haematoxilin-eosin- HE, X200 original magnification). (B) 
Moderate dysplasia showed alteration in the lower two-thirds of the epithelium layer with loss of polarity, disordered 
maturation from basal to squamous cells, increased cellular density, and basal cell hyperplasia (HE, X200 original magni-
fication). (C) In moderate dysplasia an increased cytoplasmatic and nuclear stain in the basal layer was observed. In detail, 
cytoplasmatic and nuclear stains, cytoplasmatic stains only, or the absence of stains may be observed. Also, the mosaic 
pattern may also be visualized (Streptavidine-biotine, X200 original magnification). (D) In normal oral mucosa, the meta-
llothionein immunoexpression was predominant in the basal layer (Streptavidine-biotine, X200 original magnification).
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observed in present study might indicate that the moderate 
dysplasia is the hallmark point in the process of carcino-
genesis. The major requirement for MT function might 
occur in this phase and do not suffer other alterations 
with the worsening of the histological features.
Studies have explored markers as auxiliary tool in the his-
tological assessment of OL. A gradual increase in PCNA 
and Ki-67 expression has been positively associated with 
the grade of dysplasia in OL (7,13,15). In contrast, the 
relationship between p53 overexpression and OL has been 
controversial (10). Santos-García et al. (4) observed a p53 
overexpression with the advance of the grade of severity 
histologic of OL. However, Warnakulasuriya (6) claims 
that p53, when used as a single marker, is an inappropriate 
immunohistochemical marker for the prediction of tumor 
development in high-risk patients. Chattopadhyay et al. 
(14) observed that the mean AgNOR count increase, in 
accordance with the dysplasia grade, may indeed be an 
additional tool in distinguishing between OL with dys-
plasia and without dysplasia. 
Ioachim et al. (25) identified a positive correlation between 
MT and PCNA expression in potentially malignant lesions 
of  the larynx. However, no association was observed 
between MT and p53. Ostrakhovitch et al. (29) demons-
trated, “in vitro” and “in vivo”, a possible association 
between MT and p53 in breast cancer epithelial cells and 
suggested that the co-expression of these proteins may be 
related to the control of apoptosis. The p53 binds to DNA 
impede transcription through a zinc-dependent process. 
Metal-chelanting agents, such as MT, can remove zinc, 
therefore inducing a reversible conformation change in 
wild type p53, blocking its action (30). Future evaluations 
are necessary to clarify the association of these markers 
with MT in OL.
The mosaic stain pattern, or the heterogeneity for MT 
labeling intensity observed, was also verified in oral squa-
mous cell carcinoma (20), and renal cell carcinoma (17). 
Cardoso et al. (20) suggested that this pattern may be due 
to the phenotypic variations among neoplasic cells. This 
application to dysplastic cells might be worthy of a more 
meticulous investigation.
Although the clinical data of OL has been correlated with 
increased risk of malignant change, in this study, no signi-
ficant difference was observed in MT total indexes between 
regions of high and low risk. This study only detected a 
tendency of MT overexpression in regions of high risk. 
In conclusion, this study suggests that the MT may be a 
marker to moderate dysplasia and may play a role in oral 
carcinogenesis.
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